2009 Calendar, Coverage, Slides, etc.
==> The Robins Group Coverage (Dec. 3, 2008)
Note: Earnings Estimate for Calendar 2009 is 0.14
http://www.therobinsgroup.biz/files/12_03_08_AEMD_IC.pdf
==> Latest Letter to Shareholders (Feb. 24, 2009)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1259383&highlight=
==> Video of RedChip Conference Presentation, accompanying slides and follow-up RedChipTV interview (Mar. 24, 2009)
http://www.redchip.com/visibility/conferencePages/SanFran2009/conferenceMain.asp?page=archive
==> Latest CEO Webcast (Mar. 5, 2009)
http://www.ceocast.com/(1t5vjl331gce04nvkcnow433)/company.aspx?id=1049
==> Current Chart TA
http://www.stockta.com/cgi-bin/analysis.pl?symb=AEMD&num1=13&cobrand=&mode=stock
==> Updated 2009 Calendar
**Note that I will be bolding the milestones that have been acheived as I update this periodically.
March:
1. Results from HIV study (DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1265082&highlight=
2. Results from 30-day HCV study (Semi-Done)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1269792&highlight=
April:
1. Notification on potential award from Bill and Melinda Gates Foundation
And regarding this potential grant, lets not forget the Nov 2007 announcement:
American India Foundation To Honor Aethlon Medical CEO
SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2007--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, disclosed today that its Chairman and CEO, James A. Joyce, will be presented the "Spirit of India" award at the America India Foundation (AIF) annual gala on December 1, 2007. The event, sponsored by the Bill & Melinda Gates Foundation, honors American business leaders who have demonstrated a commitment to accelerating social and economic change in India.
May/June:
1. Notification on potential 5-year contract award from BARDA/fed gov
2. Release of Annual Report
3. Completion of GMP Manufacturing and Quality Systems to allow commerical export
Other 2009 Milestones (targeted month unknown):
1. Announcment of agreement to treat Dengue Fever in India
Note recent addition to team of Director of Business Development from India, http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1248744&highlight=
2. Establish data-supported HIV strategy for Undetectable Viral Load
3. Close on strategic partnership(s) and negotiate strategic investment
4. Announcment on the planned contract production partner referenced in the investment firm write-up (Done)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1262531&highlight=
5. Initiation of commerical production for sale of product in India
6. Starting of clinical trials in U.S. involving 10-patient safety study mimicing what has already been conducted in India (Described by CEO as near-term objective at RedChip Conference)
7. Define regulatory and commericalization plan for European Union
8. Complete currently ongoing in-vitro Cytomegalovirus study
9. Announce research plan and progress to concetnrate and subsequently identify new viruses underlying specific diseases and identify biomarkers that can be targetes for drug intervention.
10. Announce research progress to advance adjunct cancer treatment possibilities.
==> The Robins Group Coverage (Dec. 3, 2008)
Note: Earnings Estimate for Calendar 2009 is 0.14
http://www.therobinsgroup.biz/files/12_03_08_AEMD_IC.pdf
==> Latest Letter to Shareholders (Feb. 24, 2009)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1259383&highlight=
==> Video of RedChip Conference Presentation, accompanying slides and follow-up RedChipTV interview (Mar. 24, 2009)
http://www.redchip.com/visibility/conferencePages/SanFran2009/conferenceMain.asp?page=archive
==> Latest CEO Webcast (Mar. 5, 2009)
http://www.ceocast.com/(1t5vjl331gce04nvkcnow433)/company.aspx?id=1049
==> Current Chart TA
http://www.stockta.com/cgi-bin/analysis.pl?symb=AEMD&num1=13&cobrand=&mode=stock
==> Updated 2009 Calendar
**Note that I will be bolding the milestones that have been acheived as I update this periodically.
March:
1. Results from HIV study (DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1265082&highlight=
2. Results from 30-day HCV study (Semi-Done)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1269792&highlight=
April:
1. Notification on potential award from Bill and Melinda Gates Foundation
And regarding this potential grant, lets not forget the Nov 2007 announcement:
American India Foundation To Honor Aethlon Medical CEO
SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2007--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, disclosed today that its Chairman and CEO, James A. Joyce, will be presented the "Spirit of India" award at the America India Foundation (AIF) annual gala on December 1, 2007. The event, sponsored by the Bill & Melinda Gates Foundation, honors American business leaders who have demonstrated a commitment to accelerating social and economic change in India.
May/June:
1. Notification on potential 5-year contract award from BARDA/fed gov
2. Release of Annual Report
3. Completion of GMP Manufacturing and Quality Systems to allow commerical export
Other 2009 Milestones (targeted month unknown):
1. Announcment of agreement to treat Dengue Fever in India
Note recent addition to team of Director of Business Development from India, http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1248744&highlight=
2. Establish data-supported HIV strategy for Undetectable Viral Load
3. Close on strategic partnership(s) and negotiate strategic investment
4. Announcment on the planned contract production partner referenced in the investment firm write-up (Done)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1262531&highlight=
5. Initiation of commerical production for sale of product in India
6. Starting of clinical trials in U.S. involving 10-patient safety study mimicing what has already been conducted in India (Described by CEO as near-term objective at RedChip Conference)
7. Define regulatory and commericalization plan for European Union
8. Complete currently ongoing in-vitro Cytomegalovirus study
9. Announce research plan and progress to concetnrate and subsequently identify new viruses underlying specific diseases and identify biomarkers that can be targetes for drug intervention.
10. Announce research progress to advance adjunct cancer treatment possibilities.
Recent AEMD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:18 PM
- Advancements in Novel Immunotherapeutics in The Oncology Battle • Newsfile • 03/24/2026 02:30:00 PM
- Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review • PR Newswire (US) • 03/24/2026 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 01:15:09 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities • PR Newswire (US) • 03/12/2026 12:01:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th • GlobeNewswire Inc. • 03/06/2026 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:15:32 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 02:54:05 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/18/2026 01:22:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 10:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:15:44 PM
- Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update • PR Newswire (US) • 02/12/2026 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 • PR Newswire (US) • 02/04/2026 01:01:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/27/2026 09:15:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/27/2026 09:15:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2026 10:15:32 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/16/2026 10:14:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/16/2026 09:15:44 PM
